Morgan Stanley and Pfizer

Selected healthcare news for the capital firm - Morgan Stanley, and the company - Pfizer. We have 624 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
12/14/2021 Adagio Therapeutics Tumbles On Omicron Data Yahoo News ... government agencies to consider the role the therapy, ADG20, can play in preventing and treating Covid-19.The news surprised Morgan Stanley after previous in vitro studies showed ADG20 retained activity against prior variants, including ... drugs utility."Related ArticlesAdagio Therapeutics Tumbles On Omicron DataPfizer shot less effective in South Africa after Omicron emerges - study2 Buy-Rated Home Improvement Stocks Surging to New 52-Week Highs ...
12/10/2021 Moderna Slides As Flu Vaccine Data Disappoint ... development of one of the first mRNA-based COVID vaccines, were down more than 10% in premarket trading Friday after Morgan Stanley warned the early-stage flu vaccine trial data had disappointed analysts who were ... variant and talking up the need for more jabs (Moderna, Pfizer and other major vaccine producers have all promised to have an omicron-targeting jab ready in three months).Tyler DurdenFri, 12/10/2021 ‚Ai 08:44 ...
12/9/2021 Upgrades and Downgrades for Thursday, 12/9 ... from Hold to Buy- Yum! Brands (YUM) upgraded by Atlantic Equities from Neutral to Overweight- United Rentals (URI) upgraded by Morgan Stanley from Underweight to Equal Weight- EngageSmart (ESMT) upgraded by Citi from Neutral to ... Cisco (CSCO) upgraded by Erste Group from Hold to Buy- Pfizer (PFE) upgraded by Erste Group from Hold to Buy- Whitehaven Coal (WHITF) upgraded by Citi from Neutral to Buy- Twilio (TWLO) upgraded by Barclays ...
11/29/2021 3 Pharma Stocks Morgan Stanley Says Will Be Omicron Variant Beneficiaries | Markets Insider Business Insider The news of a new variant of the coronavirus Friday sent financial markets into a tailspin. The adversity could present an opportunity for a handful of biopharma stocks, according to a Morgan Stanley analyst.The Biopharma Analyst: Matthew Harrison maintained an Equal-Weight rating on Pfizer, Inc. (NYSE: PFE ) shares and increased the price target from $50 to $60.The analyst maintained an Equal-Weight rating on Merck & Co., Inc ...
11/29/2021 3 Pharma Stocks Morgan Stanley Says Will Be Omicron Variant Beneficiaries Benzinga The news of a new variant of the coronavirus Friday sent financial markets into a tailspin. The adversity could present an opportunity for a handful of biopharma stocks, according to a Morgan Stanley analyst.The Biopharma Analyst: Matthew Harrison maintained an Equal-Weight rating on Pfizer, Inc. (NYSE: PFE ) shares and increased the price target from $50 to $60.The analyst maintained an Equal-Weight rating on Merck & Co., Inc ...
10/27/2021 Morgan Stanley Sustainable Signals: U.S. Individual Investors Maintain Strong Interest in Sustainable Investing Despite COVID-19 Pandemic TMCnet News [October 27, 2021] Morgan Stanley Sustainable Signals: U.S. Individual Investors Maintain Strong Interest in Sustainable Investing Despite COVID-19 PandemicFour in five U.S. individual investors remained focused on sustainable investing during the ... former Governor of the Bank of England Mark Carney, and Pfizer CEO Dr. Albert Bourla. The report examines the attitudes, perceptions and behaviors of individual investors with respect to sustainable investing. Following three prior Sustainable ...
10/23/2021 Zacks Investment Research Lowers Royalty Pharma (NASDAQ:RPRX) to Hold The Markets Daily ... biopharmaceutical industry. The compnay‚Aos portfolio includes royalties on commercial products, including AbbVie and J&J‚Aos Imbruvica, Astellas and Pfizer‚Aos Xtandi, Biogen‚Aos Tysabri, Gilead‚Aos HIV franchise, Merck‚Aos Januvia, Novartis‚Ao ... buy rating and a $50.00 price target for the company. Morgan Stanley lowered their price objective on Royalty Pharma from $51.00 to $46.00 and set an equal weight rating on the stock in a report ...
10/21/2021 Royalty Pharma (NASDAQ:RPRX) Rating Lowered to Hold at Zacks Investment Research - Mayfield Recorder Mayfield Recorder ... biopharmaceutical industry. The compnay‚Aos portfolio includes royalties on commercial products, including AbbVie and J&J‚Aos Imbruvica, Astellas and Pfizer‚Aos Xtandi, Biogen‚Aos Tysabri, Gilead‚Aos HIV franchise, Merck‚Aos Januvia, Novartis‚Ao ... Au rating and a $50.00 target price on the stock. Morgan Stanley cut their price target on shares of Royalty Pharma from $51.00 to $46.00 and set an ‚Auequal weight‚Au rating on the stock ...
10/21/2021 Royalty Pharma (NASDAQ:RPRX) Cut to Hold at Zacks Investment Research - Slater Sentinel ... biopharmaceutical industry. The compnay‚Aos portfolio includes royalties on commercial products, including AbbVie and J&J‚Aos Imbruvica, Astellas and Pfizer‚Aos Xtandi, Biogen‚Aos Tysabri, Gilead‚Aos HIV franchise, Merck‚Aos Januvia, Novartis‚Ao ... Au rating and a $50.00 price objective for the company. Morgan Stanley dropped their price objective on Royalty Pharma from $51.00 to $46.00 and set an ‚Auequal weight‚Au rating for the company in a ...
10/19/2021 Royalty Pharma (NASDAQ:RPRX) Downgraded by Zacks Investment Research ... Pfizer‚Aos Xtandi, Biogen‚Aos Tysabri, Gilead‚Aos HIV franchise, Merck‚Aos Januvia, Novartis‚Ao Promacta and Vertex‚Aos Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK. ‚AuA number of other equities analysts have also recently issued reports on RPRX. Morgan Stanley lowered their target price on Royalty Pharma from $51.00 to $46.00 and set an ‚Auequal weight‚Au rating ...
10/8/2021 The three major US stock indexes closed higher across the board, the Nasdaq rose more than 1%, and the Dow once rose more than 500 points. ... Morgan Stanley fell 0.22%, Bank of America fell 0.2%, and Wells Fargo fell 0.17%. Energy stocks were mixed. Exxon Mobil rose 0.23%, Chevron rose 0.66%, ConocoPhillips fell 0.36%, Schlumberger rose 3.57%, and Occidental Petroleum rose 1.59%. Anti-epidemic concept stocks rose collectively. Moderna rose 2.29%, Gilead Sciences rose 0.98%, Novavax Pharmaceuticals rose 2.34%, BioNTech rose 4.42%, and Pfizer rose 1.74%. Most popular Chinese concept stocks rose, Tuniu rose 15.67%, Qudian ...
10/5/2021 This biotech analyst thinks vaccination is the ‚Äúonly way‚Äù to end the pandemic ... Pfizer will report trial results for its oral COVID-19 drug later this year. ‚AuWinter is coming‚Au ‚Ai could it fuel another surge in COVID-19 cases in the United States? Morgan Stanley‚Aos biotech analyst Matthew Harrison thinks so. But on a more positive note, he expects this to be the last ‚Ausubstantial increase‚Au in the U.S. Harrison‚Aos remarks on CNBC‚Aos ‚AuWorldwide Exchange‚Au Are ...
10/2/2021 Why Merck Shares Soar as Vaccine Makers Decline on New Anti-Covid Drug ... said its experimental Covid-19 drug reduced hospitalizations and deaths in people early on in coronavirus infection. In a report, Morgan Stanley analysts Matthew Harrison, Charlie Yang and Kostas Biliouris recalled that Merck already has ... developed Covid-19 vaccines are falling, albeit to varying degrees. Pfizer shares are down 0.7% to US$42.71, Johnson & Johnson shares are down 0.48% to US$160.73, after coming down stronger in the morning. But ...
9/30/2021 A COVID-19 pill could soon fill a gap in our pandemic response that vaccines can't overcome Pills photo stylized 3 Companies are racing to develop a pill that can treat COVID-19.Drugmakers like Pfizer and Merck expect results on their oral-antiviral programs before year-end.An effective, easy-to ... lower people's risk perception of the pandemic," Matthew Harrison, a Morgan Stanley biotech analyst, wrote in a September 27 research note.While excitement is building as the pharmaceutical giants launch more studies, don't expect a ...
9/29/2021 Dassault Aviation (OTCMKTS:DUAVF) Shares to Split on Friday, October 1st | Daily Political Daily Political ... biopharmaceutical industry. The compnay‚Aos portfolio includes royalties on commercial products, including AbbVie and J&J‚Aos Imbruvica, Astellas and Pfizer‚Aos Xtandi, Biogen‚Aos Tysabri, Gilead‚Aos HIV franchise, Merck‚Aos Januvia, Novartis‚Ao ... buy rating and a $50.00 price objective for the company. Morgan Stanley dropped their target price on Royalty Pharma from $51.00 to $46.00 and set an equal weight rating on the stock in a research ...
9/26/2021 Royalty Pharma (NASDAQ:RPRX) Lowered to Hold at Zacks Investment Research - Stock Observer ... biopharmaceutical industry. The compnay‚Aos portfolio includes royalties on commercial products, including AbbVie and J&J‚Aos Imbruvica, Astellas and Pfizer‚Aos Xtandi, Biogen‚Aos Tysabri, Gilead‚Aos HIV franchise, Merck‚Aos Januvia, Novartis‚Ao ... buy rating and a $50.00 target price for the company. Morgan Stanley cut their target price on Royalty Pharma from $51.00 to $46.00 and set an equal weight rating on the stock in a research ...
9/25/2021 Royalty Pharma (NASDAQ:RPRX) Downgraded by Zacks Investment Research ... biopharmaceutical industry. The compnay‚Aos portfolio includes royalties on commercial products, including AbbVie and J&J‚Aos Imbruvica, Astellas and Pfizer‚Aos Xtandi, Biogen‚Aos Tysabri, Gilead‚Aos HIV franchise, Merck‚Aos Januvia, Novartis‚Ao ... buy rating and a $50.00 target price on the stock. Morgan Stanley reduced their target price on shares of Royalty Pharma from $51.00 to $46.00 and set an equal weight rating for the company in ...
9/21/2021 The Market Sum: Dramatic Drop U.S. equity markets suffer their biggest one-day loss since May on worries about China & U.S. debt. To view this email as a web page, click here.By Caleb Silver , Editor in Chief & Bill McColl , Newsletter Contributor By Caleb Silver , Editor in Chief& Bill McColl , Newsletter Contributor Photo courtesy Getty Images / Handout / Handout1 / U.S. equity markets plunge on China, U.S. debt fears2 / Morgan Stanley's bear warning3 / Pfizer ...
9/20/2021 Pfizer, BioNTech Analysts On FDA Panel's COVID-19 Booster Dose Decision Benzinga Pfizer, Inc. (NYSE: PFE )-BioNTech SE (NASDAQ: BNTX ) suffered a setback last week after a FDA panel did not recommend a third dose of the duo's COVID-19 vaccine for the broader population . The Pfizer-BioNTech Analysts: Morgan Stanley analyst Matthew Harrison maintained an Equal-weight rating and $45 price target for Pfizer shares. BofA Securities analyst Tazeen Ahmad reiterated a Neutral rating and $407 rating on BioNTech shares. Adcom ...
9/20/2021 Pfizer, BioNTech Analysts On FDA Panel's COVID-19 Booster Dose Decision | Markets Insider Business Insider Pfizer, Inc. (NYSE: PFE )- BioNTech SE (NASDAQ: BNTX ) suffered a setback last week after a FDA panel did not recommend a third dose of the duo's COVID-19 vaccine for the broader population.The Pfizer-BioNTech Analysts: Morgan Stanley analyst Matthew Harrison maintained an Equal-weight rating and $45 price target for Pfizer shares.BofA Securities analyst Tazeen Ahmad reiterated a Neutral rating and $407 rating on BioNTech shares.Adcom ...
9/18/2021 Royalty Pharma (NASDAQ:RPRX) Cut to Hold at Zacks Investment Research - Slater Sentinel ... Pfizer‚Aos Xtandi, Biogen‚Aos Tysabri, Gilead‚Aos HIV franchise, Merck‚Aos Januvia, Novartis‚Ao Promacta and Vertex‚Aos Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK. ‚AuGet Royalty Pharma alerts: Several other equities research analysts have also recently weighed in on RPRX. Morgan Stanley decreased their target price on Royalty Pharma from $51.00 to $46.00 and set an equal ...
9/18/2021 SVB Leerink Reaffirms “Hold” Rating for Pfizer (NYSE:PFE) SVB Leerink restated their hold rating on shares of Pfizer (NYSE:PFE) in a research report report published on Tuesday, Analyst Ratings Network reports. The brokerage currently has a $49.00 price objective on the biopharmaceutical ... buy rating and a $43.00 price objective on the stock. Morgan Stanley raised their price objective on shares of Pfizer from $42.00 to $45.00 and gave the company an equal weight rating in a research ...
9/16/2021 Royalty Pharma (NASDAQ:RPRX) Stock Rating Lowered by Zacks Investment Research ... biopharmaceutical industry. The compnay‚Aos portfolio includes royalties on commercial products, including AbbVie and J&J‚Aos Imbruvica, Astellas and Pfizer‚Aos Xtandi, Biogen‚Aos Tysabri, Gilead‚Aos HIV franchise, Merck‚Aos Januvia, Novartis‚Ao ... buy rating and a $50.00 price target on the stock. Morgan Stanley cut their target price on Royalty Pharma from $51.00 to $46.00 and set an equal weight rating on the stock in a research ...
9/16/2021 Babies could be given Pfizer's Covid vaccine in the US this winter: Read more on this subject: Vaccines and Vaccinations News Story Source: https://www.dailymail.co, By CONNOR BOYD Pfizer's Covid vaccine could be rolled out to babies as young as six months in the US this winter ... we would file with the FDA,' D'Amelio said at the Morgan Stanley Global Healthcare Conference. 'I'll call it in the weeks shortly thereafter the filing of the data for the five- to 11-year-olds ...
8/26/2021 Breaking News: Many Manhattan employers plan to require workers to be vaccinated That's according to a new survey by the Partnership for New York City, one of the city's most influential business groups, which represents massive employers like Goldman Sachs, IBM, Pfizer, Morgan Stanley and BlackRock. August 25, 2021 Breaking News Many Manhattan employers plan to require workers to be vaccinated, survey saysBy Liz Young / That's according to a new survey by the Partnership for New York City, one of the ...